We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M
Read MoreHide Full Article
Ionis Pharmaceuticals, Inc. (IONS - Free Report) announced that it has out-licensed IONIS-AZ5-2.5Rx, a Generation 2.5 antisense drug, to AstraZeneca (AZN - Free Report) . The candidate will be developed to treat a genetically associated form of kidney disease.
AstraZeneca will be responsible for the development and commercialization of the candidate, going forward. Ionis entered a strategic collaboration with AstraZeneca in 2012 to develop treatment for cardiovascular, metabolic and renal diseases. This is the second drug to enter development under this agreement.
Per the terms of the deal, Ionis will receive an upfront payment of $30 million from AstraZeneca and is eligible to receive up to $300 million in the form of milestone payments and royalty payments on potential sales.
Ionis’s shares have risen 9.5% in the past year, outperforming the industry’s gain of 1.8% in that period.
Ionis has collaboration agreements with several pharma companies to whom it licenses and sells its technology on an exclusive or non-exclusive basis for fees and payments.
Ionis earns the majority of its revenues in the form of royalty from Biogen (BIIB - Free Report) on sales of spinal muscular atrophy drug, Spinraza. The drug was developed using Ionis’ antisense technology. Several other candidates are under development in collaboration with Biogen.
We note that in August 2017, Ionis retained all rights to its lead pipeline candidate, Inotersen, as Glaxo (GSK - Free Report) declined its option to develop the drug. Investors cheered the news as Ionis will record full sales instead of royalties upon successful commercialization, which is expected in 2018.
Ionis is scheduled to report its fourth quarter and full year 2017 results on Feb 27. We expect to get updates on its various pipeline candidates.
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M
Ionis Pharmaceuticals, Inc. (IONS - Free Report) announced that it has out-licensed IONIS-AZ5-2.5Rx, a Generation 2.5 antisense drug, to AstraZeneca (AZN - Free Report) . The candidate will be developed to treat a genetically associated form of kidney disease.
AstraZeneca will be responsible for the development and commercialization of the candidate, going forward. Ionis entered a strategic collaboration with AstraZeneca in 2012 to develop treatment for cardiovascular, metabolic and renal diseases. This is the second drug to enter development under this agreement.
Per the terms of the deal, Ionis will receive an upfront payment of $30 million from AstraZeneca and is eligible to receive up to $300 million in the form of milestone payments and royalty payments on potential sales.
Ionis’s shares have risen 9.5% in the past year, outperforming the industry’s gain of 1.8% in that period.
Ionis has collaboration agreements with several pharma companies to whom it licenses and sells its technology on an exclusive or non-exclusive basis for fees and payments.
Ionis earns the majority of its revenues in the form of royalty from Biogen (BIIB - Free Report) on sales of spinal muscular atrophy drug, Spinraza. The drug was developed using Ionis’ antisense technology. Several other candidates are under development in collaboration with Biogen.
We note that in August 2017, Ionis retained all rights to its lead pipeline candidate, Inotersen, as Glaxo (GSK - Free Report) declined its option to develop the drug. Investors cheered the news as Ionis will record full sales instead of royalties upon successful commercialization, which is expected in 2018.
Ionis is scheduled to report its fourth quarter and full year 2017 results on Feb 27. We expect to get updates on its various pipeline candidates.
Ionis Pharmaceuticals, Inc. Price
Ionis Pharmaceuticals, Inc. Price | Ionis Pharmaceuticals, Inc. Quote
Zacks Rank
Ionis Pharma carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>